Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LOSEASONIQUE vs ALYACEN 7/7/7
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination of ethinyl estradiol and drospirenone; ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation; drospirenone is a progestin with anti-mineralocorticoid and anti-androgenic activity.
Combination of norethindrone (progestin) and ethinyl estradiol (estrogen) that inhibits gonadotropin release from the pituitary, suppressing ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.
Prevention of pregnancy,Treatment of moderate acne vulgaris in women at least 14 years old who have achieved menarche and desire an oral contraceptive,Treatment of premenstrual dysphoric disorder (PMDD) in women who choose to use an oral contraceptive
Prevention of pregnancy
One tablet (ethinyl estradiol 0.02 mg/levonorgestrel 0.1 mg) orally once daily for 21 days, followed by 7 days of placebo.
ALYACEN 7/7/7 is a combination oral contraceptive containing ethinyl estradiol 0.02 mg and drospirenone 3 mg. One tablet taken orally once daily for 28 days (7 active, 7 placebo, 7 active) without a hormone-free interval.
Terminal elimination half-life is 12-15 hours, supporting once-daily dosing.
Terminal elimination half-life is 14 hours (range 12-16 h) in healthy adults; prolonged to 24-30 h in moderate renal impairment (Cr Cl 30-50 m L/min).
Ethinyl estradiol: primarily metabolized by CYP3A4, undergoes conjugation and enterohepatic recirculation. Drospirenone: extensively metabolized by CYP3A4, with minor involvement of CYP1A1 and CYP2C9; forms two major metabolites (dihydrodrospirenone and drospirenone sulfate) that are not pharmacologically active.
Norethindrone: primarily hepatic via reduction and conjugation, with CYP3A4 involvement. Ethinyl estradiol: primarily via CYP3A4, also undergoes sulfation and glucuronidation.
Renal: ~50% as metabolites; fecal: ~30% as metabolites; biliary: minor.
Renal: ~50% (unchanged drug); Fecal: ~20% (via bile); Biliary: ~30% (metabolites). Total clearance is 12 L/h.
Ethinyl estradiol: ~97% bound to albumin; progestin: ~99% bound to SHBG and albumin.
98% bound primarily to albumin; minor binding to alpha-1-acid glycoprotein.
Ethinyl estradiol: 4-5 L/kg; progestin: 2-3 L/kg; indicates extensive tissue distribution.
0.35 L/kg (total body water distribution); in obesity, Vd increases to 0.5 L/kg due to lipophilicity.
Oral: ~40-60% for ethinyl estradiol due to first-pass metabolism; progestin: >80%.
Oral: 85% (with high-fat meal reduces to 70%); Sublingual: 90%.
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal impairment or acute renal failure.
Contraindicated in patients with severe renal impairment (Cr Cl <30 m L/min) or acute renal failure due to drospirenone's antimineralocorticoid activity. No dose adjustment recommended for mild to moderate impairment (Cr Cl ≥30 m L/min).
Contraindicated in Child-Pugh Class B or C hepatic impairment; no specific dose adjustment defined for mild impairment but use with caution.
Contraindicated in patients with acute hepatic disease, hepatic tumors, or impaired liver function (Child-Pugh class B or C). Discontinue if jaundice or pruritus develops. No dose adjustment for Child-Pugh class A.
Safety and efficacy established in females of reproductive age; postmenarche use as per adult dosing. Not indicated before menarche.
Not indicated for use in pediatric patients before menarche. Safety and efficacy in postmenarchal adolescents are expected to be similar to adults; dose is same as adults.
Not indicated for use in postmenopausal women; no geriatric-specific dosing.
Not indicated for use in postmenopausal women. No recommendations for geriatric population due to lack of indication.
Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive use. This risk increases with age, especially in women over 35 years, and with the number of cigarettes smoked. Women who use combination hormonal contraceptives should be strongly advised not to smoke.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives (COCs). Risk increases with age and amount smoked (especially >15 cigarettes/day). Women over 35 who smoke should not use COCs.
Thrombotic disorders (venous thromboembolism, arterial thromboembolism, stroke, myocardial infarction),Hepatic disease (acute hepatitis, benign/malignant liver tumors),Hypertension (contraindicated if uncontrolled),Gallbladder disease,Carbohydrate/lipid metabolism effects,Headache (including migraine with focal aura),Uterine bleeding irregularities,Depression,Fluid retention,Ocular lesions (retinal thrombosis),Cervical cancer screening,Hereditary angioedema,Chloasma,Drug interactions (especially CYP3A4 inducers),Laboratory test interference (sex hormone-binding globulin, thyroid-binding globulin)
Thrombotic disorders (thrombophlebitis, pulmonary embolism, cerebral hemorrhage, myocardial infarction),Cerebrovascular disease,Carcinoma of the breast or reproductive organs,Hepatic adenoma or carcinoma,Ocular lesions (retinal thrombosis, papilledema),Gallbladder disease,Carbohydrate/lipid effects,Elevated blood pressure,Hereditary angioedema,Chloasma,Hepatic impairment
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast cancer,Endometrial cancer or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma,Known or suspected pregnancy,Uncontrolled hypertension (BP ≥ 160/100 mm Hg),Diabetes with vascular involvement,Headache with focal neurological symptoms (migraine with aura) in women over 35,Major surgery with prolonged immobilization,Heavy smoking (≥15 cigarettes/day) in women over 35,Hypersensitivity to any component of the drug
Breast cancer (current or history),Undiagnosed abnormal genital bleeding,Known or suspected pregnancy,Current or history of thrombotic disorders (DVT, PE, stroke, MI),Cerebrovascular or coronary artery disease,Valvular heart disease with complications,Severe hypertension,Diabetes with vascular disease,Headaches with focal neurological symptoms (e.g., migraine with aura),Major surgery with prolonged immobilization,Known thrombophilia (e.g., Factor V Leiden, prothrombin mutation, protein S/C deficiency),Active liver disease (tumors, hepatitis, cirrhosis),Uncontrolled hypertension,Smoking (if age >35),Hypersensitivity to any component
No specific dietary restrictions. Grapefruit may slightly increase ethinyl estradiol levels; consistent intake is advised. Alcohol in moderation does not affect efficacy. Always take with or without food consistently.
Grapefruit and grapefruit juice may increase ethinyl estradiol levels, potentially increasing side effects. St. John's wort (herbal supplement) can reduce contraceptive efficacy. No other significant food interactions; however, maintaining a stable intake of vitamin C and folate is generally recommended.
Category X. Estrogen-progestin combinations are contraindicated in pregnancy. First trimester exposure associated with risk of congenital anomalies, particularly cardiac defects and limb reduction. Second and third trimester exposure may result in fetal harm including masculinization of female genitalia (progestin effect) and possible hepatic adenoma. Discontinue immediately if pregnancy occurs.
ALYACEN 7/7/7 contains ethinylestradiol and norethindrone. First trimester: No increased risk of major birth defects based on epidemiologic studies; however, inadvertent use does not warrant termination. Second and third trimesters: Avoid use due to potential adverse effects on fetal development, including feminization of male fetuses and potential for congenital anomalies from progestin. Postnatal: Possible long-term effects on reproductive development.
Excreted in breast milk. Estrogens may reduce milk quantity and quality. M/P ratio not established. Use not recommended during breastfeeding; alternative contraception advised.
Contraindicated in breastfeeding. Ethinylestradiol reduces milk quantity and quality. Norethindrone is excreted in low amounts (M/P ratio approximately 0.3-0.4). However, combination oral contraceptives are not recommended during lactation due to estrogen effects on milk production.
No dose adjustment applicable; drug is contraindicated in pregnancy. Discontinue immediately if pregnancy occurs.
ALYACEN 7/7/7 is contraindicated in pregnancy; no dose adjustments are applicable as use is not recommended. Pharmacokinetic changes in pregnancy (increased clearance of steroids) would theoretically require higher doses, but due to fetal risks, alternative therapies should be used.
LOSEASONIQUE (ethinyl estradiol/levonorgestrel) is a combined oral contraceptive with a shortened hormone-free interval (2 days of placebo vs. typical 7 days) to reduce withdrawal bleeding duration and frequency. Counsel patients that spotting/breakthrough bleeding may occur more commonly in the first few cycles. It does not protect against STIs. Consider alternative contraception in patients with contraindications like smoking >35, hypertension, migraine with aura, or history of thromboembolism.
ALYACEN 7/7/7 is a triphasic oral contraceptive containing ethinyl estradiol and norgestimate. The 7/7/7 regimen refers to the varying doses of norgestimate across three 7-day phases (0.18 mg, 0.215 mg, 0.25 mg) with a fixed 0.025 mg ethinyl estradiol. Use consistent 7-day placebo interval. Consider increased risk of venous thromboembolism (VTE) in patients with BMI >30, smoking >15 cigarettes/day, or age >35. Monitor for breakthrough bleeding, especially during the first 3 cycles. Avoid in patients with migraine with aura, uncontrolled hypertension, or history of DVT/PE. Drug interactions with CYP3A4 inducers (e.g., rifampin, carbamazepine) may reduce efficacy; consider backup contraception.
Take one tablet daily at the same time, even during placebo days, to maintain contraceptive efficacy.,If a dose is missed, follow the package instructions; missed pills increase pregnancy risk.,Spotting or breakthrough bleeding is common in the first 3 months and usually resolves.,Do not smoke while taking this medication, especially if over 35 years old, due to increased risk of blood clots.,This medication does not protect against HIV or other sexually transmitted infections.,Use back-up contraception (e.g., condoms) if you have vomiting or severe diarrhea for more than 48 hours.,Report any signs of blood clots: sudden chest pain, shortness of breath, leg swelling/pain, or severe headache.
Take one pill daily at the same time each day, in the order specified on the pack (active pills followed by placebo).,If you miss a pill, follow the package instructions; missing pills increases pregnancy risk, especially if placebo week is extended.,Common side effects include nausea, headache, breast tenderness, and spotting, which usually improve after 2-3 cycles.,Seek immediate medical attention for severe abdominal pain, chest pain, shortness of breath, leg pain/swelling, or severe headache.,This medication does not protect against HIV/AIDS or other sexually transmitted infections (STIs).,Inform your healthcare provider if you smoke, as smoking increases risk of serious cardiovascular side effects, especially if over 35 years.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LOSEASONIQUE vs ALYACEN 7/7/7, answered by our medical review team.
LOSEASONIQUE is a Oral contraceptive that works by Combination of ethinyl estradiol and drospirenone; ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation; drospirenone is a progestin with anti-mineralocorticoid and anti-androgenic activity.. ALYACEN 7/7/7 is a Oral Contraceptive that works by Combination of norethindrone (progestin) and ethinyl estradiol (estrogen) that inhibits gonadotropin release from the pituitary, suppressing ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LOSEASONIQUE and ALYACEN 7/7/7 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LOSEASONIQUE is: One tablet (ethinyl estradiol 0.02 mg/levonorgestrel 0.1 mg) orally once daily for 21 days, followed by 7 days of placebo.. The standard adult dose of ALYACEN 7/7/7 is: ALYACEN 7/7/7 is a combination oral contraceptive containing ethinyl estradiol 0.02 mg and drospirenone 3 mg. One tablet taken orally once daily for 28 days (7 active, 7 placebo, 7 active) without a hormone-free interval.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LOSEASONIQUE and ALYACEN 7/7/7 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LOSEASONIQUE is classified as Category C. Category X. Estrogen-progestin combinations are contraindicated in pregnancy. First trimester exposure associated with risk of congenital anomalies, particularly cardiac defects an. ALYACEN 7/7/7 is classified as Category C. ALYACEN 7/7/7 contains ethinylestradiol and norethindrone. First trimester: No increased risk of major birth defects based on epidemiologic studies; however, inadvertent use does n. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.